Recent studies have demonstrated NNK exerts lung tumor-specific genotoxic effects by acting as an agonist for the α7 nicotinic acetylcholine receptor, which regulates downstream activation of signaling networks involved in the promotion and progression of lung cancer, including the PI3K/AKT and MAPK/ERK pathways (37, 38). This evidence concerns the gene CHRNA7 and lung carcinoma.